![Matthieu de Kalbermatten](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de Matthieu de Kalbermatten
Entité | Type d'entité | Industrie | |
---|---|---|---|
CellProthera SAS
![]() CellProthera SAS Medical/Nursing ServicesHealth Services CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France.
5
| Holding Company | Medical/Nursing Services | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Matthieu de Kalbermatten via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
IP2IPO Innovations Ltd.
![]() IP2IPO Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services IP2IPO Innovations Ltd. provides business development and technology transfer services. The firm also provides strategic industry University partnerships, patenting, licensing, spin-out incubation and equity management services. The company was founded in 1986 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Adecco France SAS
![]() Adecco France SAS Internet Software/ServicesTechnology Services Adecco France provides online recruitment services. The company is headquartered in Villeurbanne, France. | Internet Software/Services | Corporate Officer/Principal | |
Institut de Recherche en Hématologie et Transplantation | Chairman | ||
Amarna Therapeutics BV
![]() Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Medical/Nursing Services | Chief Executive Officer |
Statistiques
Internationale
France | 5 |
Royaume-Uni | 2 |
Pays-Bas | 2 |
Sectorielle
Health Technology | 2 |
Commercial Services | 2 |
Government | 2 |
Technology Services | 2 |
Health Services | 2 |
Opérationnelle
Corporate Officer/Principal | 5 |
Chief Tech/Sci/R&D Officer | 3 |
Chief Executive Officer | 2 |
Director/Board Member | 2 |
Founder | 1 |
Relations les plus connectées
- Bourse
- Insiders
- Matthieu de Kalbermatten
- Connexions Sociétés